
Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Brookline Capital Markets decreased their FY2026 earnings per share estimates for Palisade Bio in a report released on Wednesday, November 11th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.24) per share for the year, down from their previous estimate of ($0.21). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.24) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.35) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at $0.44 EPS.
A number of other equities analysts have also weighed in on PALI. HC Wainwright lowered their price target on shares of Palisade Bio to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 11th. Raymond James Financial started coverage on shares of Palisade Bio in a research note on Thursday, October 8th. They issued an “outperform” rating and a $6.00 target price on the stock. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. Wall Street Zen cut Palisade Bio from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $9.00.
Palisade Bio Stock Down 1.9%
Palisade Bio stock opened at $1.01 on Monday. The company has a fifty day simple moving average of $1.43 and a 200-day simple moving average of $1.81. The firm has a market capitalization of $181.07 million, a price-to-earnings ratio of -2.10 and a beta of 1.61. Palisade Bio has a 52-week low of $0.99 and a 52-week high of $2.85.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01).
Institutional Investors Weigh In On Palisade Bio
A number of hedge funds have recently modified their holdings of the company. Soleus Capital Management L.P. boosted its position in Palisade Bio by 14.8% in the 3rd quarter. Soleus Capital Management L.P. now owns 14,996,154 shares of the company’s stock valued at $20,245,000 after buying an additional 1,932,467 shares during the period. Creek Drive Management Group LLC increased its position in shares of Palisade Bio by 54.5% during the third quarter. Creek Drive Management Group LLC now owns 680,000 shares of the company’s stock worth $918,000 after acquiring an additional 240,000 shares during the period. ACT Capital Partners L.P. purchased a new stake in shares of Palisade Bio during the third quarter worth $415,000. China Universal Asset Management Co. Ltd. increased its position in shares of Palisade Bio by 19.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company’s stock worth $117,000 after acquiring an additional 13,110 shares during the period. Finally, WINTON GROUP Ltd raised its stake in shares of Palisade Bio by 180.2% in the second quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock valued at $67,000 after acquiring an additional 20,727 shares in the last quarter. Hedge funds and other institutional investors own 11.79% of the company’s stock.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Read More
- Five stocks we like better than Palisade Bio
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
